The infectious enteritis treatment market size is expected to grow by USD 403.92 million from 2021 to 2026. Moreover, the growth of the market will accelerate at a CAGR of 5.09% during the forecast period.
Request Latest Sample Report to learn about additional highlights related to market dynamics
Infectious Enteritis Treatment Market 2022-2026: Scope
The infectious enteritis treatment market report covers the following areas:
Subscribe to our "Basic Plan" billed annually at USD 5000. Get lifetime access to our Technavio Insights
Infectious Enteritis Treatment Market 2022-2026: Vendor Analysis
The infectious enteritis treatment market is fragmented, and the vendors are deploying growth strategies such as geographical expansion, product portfolio expansion, and product innovation to compete in the market. The market has intense competition due to the presence of several global, regional, and local vendors. Abbott Laboratories, Almirall SA, Cipla Ltd., Zydus Lifesciences Ltd., F. Hoffmann La Roche Ltd., Galderma SA, GlaxoSmithKline Plc, Hetero Healthcare Ltd., Mayne Pharma Group Ltd., Medimetriks Pharmaceuticals Inc., Merck KGaA, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Tolmar Pharmaceuticals Inc., and Viatris Inc. are among some of the major market participants.
To learn more about major key vendors and vendor offerings, View an Exclusive Sample Report
Infectious Enteritis Treatment Market 2022-2026: Segmentation
- Geography
- North America: North America will have significant market share growth during the forecast period. The significant rise in foodborne illnesses in countries such as the US will drive the infectious enteritis treatment market growth in North America during the forecast period. Market growth in this region will be faster than the growth of the market in Rest of World (ROW). The US and Canada are the key countries for the infectious enteritis treatment in North America.
- Europe
- Asia
- Rest Of World (ROW)
- Route of administration
- Oral: The oral segment will generate the highest market share growth during the forecast period. The rapid action of oral rehydration therapy on patients will drive the growth of the segment in the coming years.
- Injectables
Infectious Enteritis Treatment Market 2022-2026: Key Highlights
- CAGR of the market during the forecast period 2022-2026
- Detailed information on factors that will assist infectious enteritis treatment market growth during the next five years
- Estimation of the infectious enteritis treatment market size and its contribution to the parent market
- Predictions on upcoming trends and changes in consumer behavior
- The growth of the infectious enteritis treatment market
- Analysis of the market's competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of infectious enteritis treatment market, vendors
Related Reports
Herpes Zoster Therapeutics Market by Product and Geography - Forecast and Analysis 2022-2026
Nicotine Patch Market by Product and Geography - Forecast and Analysis 2022-2026
Infectious Enteritis Treatment Market Scope |
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 5.09% |
Market growth 2022-2026 |
USD 403.92 million |
Market structure |
Fragmented |
YoY growth (%) |
3.52 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 37% |
Key consumer countries |
US, Canada, Germany, UK, and China |
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
Companies profiled |
Abbott Laboratories, Almirall SA, Cipla Ltd., Zydus Lifesciences Ltd., F. Hoffmann La Roche Ltd., Galderma SA, GlaxoSmithKline Plc, Hetero Healthcare Ltd., Mayne Pharma Group Ltd., Medimetriks Pharmaceuticals Inc., Merck KGaA, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Tolmar Pharmaceuticals Inc., and Viatris Inc. |
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for the forecast period, |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Table of Contents:
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Route of Administration
- Exhibit 06: Executive Summary – Chart on Incremental Growth
- Exhibit 07: Executive Summary – Data Table on Incremental Growth
- Exhibit 08: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 09: Parent market
- Exhibit 10: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 11: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 12: Market segments
- 3.4 Market outlook: Forecast for 2021-2026
- Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
- Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
4 Five Forces Analysis
- 4.1 Five forces summary
- Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
- 4.2 Bargaining power of buyers
- Exhibit 18: Bargaining power of buyers – Impact of key factors in 2021 and 2026
- 4.3 Bargaining power of suppliers
- Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
- 4.4 Threat of new entrants
- Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
- 4.5 Threat of substitutes
- Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
- 4.6 Threat of rivalry
- Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
- 4.7 Market condition
- Exhibit 23: Chart on Market condition - Five forces 2021 and 2026
5 Market Segmentation by Route of Administration
- 5.1 Market segments
- Exhibit 24: Chart on Route of Administration - Market share 2021-2026 (%)
- Exhibit 25: Data Table on Route of Administration - Market share 2021-2026 (%)
- 5.2 Comparison by Route of Administration
- Exhibit 26: Chart on Comparison by Route of Administration
- Exhibit 27: Data Table on Comparison by Route of Administration
- 5.3 Oral - Market size and forecast 2021-2026
- Exhibit 28: Chart on Oral - Market size and forecast 2021-2026 ($ million)
- Exhibit 29: Data Table on Oral - Market size and forecast 2021-2026 ($ million)
- Exhibit 30: Chart on Oral - Year-over-year growth 2021-2026 (%)
- Exhibit 31: Data Table on Oral - Year-over-year growth 2021-2026 (%)
- 5.4 Injectables - Market size and forecast 2021-2026
- Exhibit 32: Chart on Injectables - Market size and forecast 2021-2026 ($ million)
- Exhibit 33: Data Table on Injectables - Market size and forecast 2021-2026 ($ million)
- Exhibit 34: Chart on Injectables - Year-over-year growth 2021-2026 (%)
- Exhibit 35: Data Table on Injectables - Year-over-year growth 2021-2026 (%)
- 5.5 Market opportunity by Route of Administration
- Exhibit 36: Market opportunity by Route of Administration ($ million)
6 Customer Landscape
- 6.1 Customer landscape overview
- Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
7 Geographic Landscape
- 7.1 Geographic segmentation
- Exhibit 38: Chart on Market share by geography 2021-2026 (%)
- Exhibit 39: Data Table on Market share by geography 2021-2026 (%)
- 7.2 Geographic comparison
- Exhibit 40: Chart on Geographic comparison
- Exhibit 41: Data Table on Geographic comparison
- 7.3 North America - Market size and forecast 2021-2026
- Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
- Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)
- 7.4 Europe - Market size and forecast 2021-2026
- Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
- Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
- 7.5 Asia - Market size and forecast 2021-2026
- Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
- Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
- 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
- Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- 7.7 US - Market size and forecast 2021-2026
- Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
- Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)
- 7.8 Germany - Market size and forecast 2021-2026
- Exhibit 62: Chart on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 63: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 64: Chart on Germany - Year-over-year growth 2021-2026 (%)
- Exhibit 65: Data Table on Germany - Year-over-year growth 2021-2026 (%)
- 7.9 China - Market size and forecast 2021-2026
- Exhibit 66: Chart on China - Market size and forecast 2021-2026 ($ million)
- Exhibit 67: Data Table on China - Market size and forecast 2021-2026 ($ million)
- Exhibit 68: Chart on China - Year-over-year growth 2021-2026 (%)
- Exhibit 69: Data Table on China - Year-over-year growth 2021-2026 (%)
- 7.10 UK - Market size and forecast 2021-2026
- Exhibit 70: Chart on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 71: Data Table on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 72: Chart on UK - Year-over-year growth 2021-2026 (%)
- Exhibit 73: Data Table on UK - Year-over-year growth 2021-2026 (%)
- 7.11 Canada - Market size and forecast 2021-2026
- Exhibit 74: Chart on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 75: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 76: Chart on Canada - Year-over-year growth 2021-2026 (%)
- Exhibit 77: Data Table on Canada - Year-over-year growth 2021-2026 (%)
- 7.12 Market opportunity by geography
- Exhibit 78: Market opportunity by geography ($ million)
8 Drivers, Challenges, and Trends
- 8.3 Impact of drivers and challenges
- Exhibit 79: Impact of drivers and challenges in 2021 and 2026
9 Vendor Landscape
- 9.2 Vendor landscape
- Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
- 9.3 Landscape disruption
- Exhibit 81: Overview on factors of disruption
- 9.4 Industry risks
- Exhibit 82: Impact of key risks on business
10 Vendor Analysis
- 10.1 Vendors covered
- Exhibit 83: Vendors covered
- 10.2 Market positioning of vendors
- Exhibit 84: Matrix on vendor position and classification
- 10.3 Abbott Laboratories
- Exhibit 85: Abbott Laboratories - Overview
- Exhibit 86: Abbott Laboratories - Business segments
- Exhibit 87: Abbott Laboratories - Key news
- Exhibit 88: Abbott Laboratories - Key offerings
- Exhibit 89: Abbott Laboratories - Segment focus
- 10.4 Almirall SA
- Exhibit 90: Almirall SA - Overview
- Exhibit 91: Almirall SA - Product / Service
- Exhibit 92: Almirall SA - Key news
- Exhibit 93: Almirall SA - Key offerings
- 10.5 Cipla Ltd.
- Exhibit 94: Cipla Ltd. - Overview
- Exhibit 95: Cipla Ltd. - Business segments
- Exhibit 96: Cipla Ltd. - Key news
- Exhibit 97: Cipla Ltd. - Key offerings
- Exhibit 98: Cipla Ltd. - Segment focus
- 10.6 F. Hoffmann La Roche Ltd.
- Exhibit 99: F. Hoffmann La Roche Ltd. - Overview
- Exhibit 100: F. Hoffmann La Roche Ltd. - Business segments
- Exhibit 101: F. Hoffmann La Roche Ltd. - Key news
- Exhibit 102: F. Hoffmann La Roche Ltd. - Key offerings
- Exhibit 103: F. Hoffmann La Roche Ltd. - Segment focus
- 10.7 Galderma SA
- Exhibit 104: Galderma SA - Overview
- Exhibit 105: Galderma SA - Product / Service
- Exhibit 106: Galderma SA - Key news
- Exhibit 107: Galderma SA - Key offerings
- 10.8 GlaxoSmithKline Plc
- Exhibit 108: GlaxoSmithKline Plc - Overview
- Exhibit 109: GlaxoSmithKline Plc - Business segments
- Exhibit 110: GlaxoSmithKline Plc - Key news
- Exhibit 111: GlaxoSmithKline Plc - Key offerings
- Exhibit 112: GlaxoSmithKline Plc - Segment focus
- 10.9 Hetero Healthcare Ltd.
- Exhibit 113: Hetero Healthcare Ltd. - Overview
- Exhibit 114: Hetero Healthcare Ltd. - Product / Service
- Exhibit 115: Hetero Healthcare Ltd. - Key offerings
- 10.10 Medimetriks Pharmaceuticals Inc.
- Exhibit 116: Medimetriks Pharmaceuticals Inc. - Overview
- Exhibit 117: Medimetriks Pharmaceuticals Inc. - Product / Service
- Exhibit 118: Medimetriks Pharmaceuticals Inc. - Key offerings
- 10.11 Pfizer Inc.
- Exhibit 119: Pfizer Inc. - Overview
- Exhibit 120: Pfizer Inc. - Product / Service
- Exhibit 121: Pfizer Inc. - Key news
- Exhibit 122: Pfizer Inc. - Key offerings
- 10.12 Viatris Inc.
- Exhibit 123: Viatris Inc. - Overview
- Exhibit 124: Viatris Inc. - Business segments
- Exhibit 125: Viatris Inc. - Key offerings
- Exhibit 126: Viatris Inc. - Segment focus
11 Appendix
- 11.2 Inclusions and exclusions checklist
- Exhibit 127: Inclusions checklist
- Exhibit 128: Exclusions checklist
- 11.3 Currency conversion rates for US$
- Exhibit 129: Currency conversion rates for US$
- 11.4 Research methodology
- Exhibit 130: Research methodology
- Exhibit 131: Validation techniques employed for market sizing
- Exhibit 132: Information sources
- 11.5 List of abbreviations
- Exhibit 133: List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
Share this article